<DOC>
	<DOCNO>NCT01817855</DOCNO>
	<brief_summary>This study investigate safety , tolerability , pharmacokinetics pharmacodynamics multiple ascend dos AZD7624 healthy subject patient chronic obstructive pulmonary disease .</brief_summary>
	<brief_title>To Assess Safety , Tolerability , Pharmacokinetics AZD7624 Healthy Volunteers COPD Patients</brief_title>
	<detailed_description>A Phase I , Randomized , DoubleBlind Placebo-Controlled Study Investigate Safety , Tolerability Pharmacokinetics Multiple Ascending Inhaled Doses ( MAD ) AZD7624 Healthy Subjects Patients COPD</detailed_description>
	<criteria>Healthy male and/or female subject age 18 55 year ( inclusive ) suitable vein cannulation repeat venipuncture . Provision sign date , write informed consent prior study specific procedure Plasma myoglobin CK upper reference range analyse laboratory Day 1 Male and/or female patient COPD age above18 year suitable vein cannulation repeat venipuncture . Clinical diagnosis COPD 1 year Visit 1 , accord Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline Any clinically important illness , medical/surgical procedure trauma within 4 week first administration IP Receipt another new chemical entity ( define compound approve marketing ) participation clinical study include drug treatment within least 3 month first administration IP study Any clinically important abnormality clinical chemistry , haematology urinalysis result judge Investigator Any positive result screen serum hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody human immunodeficiency virus ( HIV ) History presence gastrointestinal , hepatic renal disease condition know interfere absorption , distribution , metabolism excretion drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Phase 1 ,</keyword>
	<keyword>Safety ,</keyword>
	<keyword>Tolerability ,</keyword>
	<keyword>Healthy ,</keyword>
	<keyword>COPD patient</keyword>
</DOC>